Clinical and Pharmaceutical Studies

Funder – Univ of South FL (Prime sponsor: NIH and others)

Title – Type 1 Diabetes TrialNet Study



The Type 1 Diabetes TrialNet is an international diabetes trial network of cooperative clinical research groups to create a stable, high quality infrastructure needed for the conduct of effective and efficient clinical trials in diabetes.

Funder – Eli Lilly & Co

Title – A Randomized, Double-Blinded Study with an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide with Placebo in Pediatric Patients with Type 2 Diabetes Mellitus (AWARD-PEDS) H9X-MC-GBG


Clinical trial of a novel therapy for children with Diabetes Type2.

Funder – Lurie Children’s (Prime sponsor: NIH)

Title – Effectiveness of an e-health intervention


UIC is a site for this trial, led by Lurie Children’s Hospital, which aims to determine effectiveness of the use of technology for care support in minority children with diabetes.

Funder – Harvard School of Public Health (Prime sponsor: NIH NICHD)

Title – Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC): Smart


The Pediatric HIV/AIDS Cohort Study is a longitudinal cohort study investigating the long-term effects of HIV infection and ARV (antiretroviral) medications in children and young adults who were born with HIV or born exposed to HIV. The study follows newborns, young children, adolescents, and young adults.

Funder – IL Dept of Public Health (IDPH)

Title – Regionalized Care in the Treatment of Biochemical Genetic Diseases Detected from State of IL Newborn

Funder – NNHS (UK)

Title –Marie Sklodowska-Curie Actions – Research and Innovation Staff Exchange


The role of Dr. Hsu and UIC Sickle Cell Center role will be specifically to “train the trainers” on sickle cell disease Community Health Workers and Implementation Science, including.

(1) In short courses and workshops, Dr. Lewis Hsu will train ARISE personnel in the principles of Community Health Workers (CHW) and Implementation Science, and practical application to sickle cell disease. The  “train the trainer” approach will equip the ARISE personnel to identify local stakeholders in sickle cell, align the goals of these multiple stakeholder groups when introducing new programs, assess their readiness for change, and empower the stakeholders in continuous evaluation of program quality.

(2) ARISE exchange personnel may apply for courses at UIC, which has College of Medicine, College of Nursing, College of Pharmacy, College of Applied Health Sciences, School of Public Health, College of Business Administration, College of Education, College of Dentistry, College of Engineering, College of Urban Planning and Public Affairs, College of Social Work, College of Liberal Arts and Sciences.

(3) Regular check-in with the African and European faculty on program outcomes and sustainability. They will encourage publication of these Implementation Science experiences, which will facilitate further development of sickle cell programs in sub-Saharan Africa.

Funder – Medical University South Carolina (Prime sponsor: NIH)


Abstract: DISPLACE is a national, 28-site study, looking at what keeps some children from getting transcranial Doppler exams.  Strokes are a common concern for people with sickle cell disease. Sickle cells are misshaped red blood cells that don’t flow easily in the body. They can clump up in brain arteries, damaging the walls of blood vessels and leading to strokes. A transcranial Doppler, or TCD, measures how quickly blood is flowing through vessels in the brain. If we do a TCD and it’s abnormal, you can start transfusion therapy and prevent stroke.  Why doesn’t every child with sickle disease get transcranial Doppler screening as often as needed? That’s what the study will find out.

Funder – Children’s Hospital of Philadelphia (Prime sponsor: NIH)

Title – Chronic Kidney Disease in Children

Abstract: Chronic kidney disease (CKD) is a life-long condition that often results in substantial morbidity and premature death due to complications from a progressive decrease in kidney function. The early detection of, and initiation of therapy for, CKD is key to delaying or preventing progression to end-stage renal disease (ESRD). The CKiD (Chronic Kidney Disease in Children) study is a prospective cohort study of children with CKD that investigates risk factors and outcomes of the disease.

Title –  Improving Children’s Oncology Group Clinical Trials Enrollment Through a Novel Tri-institutional Program and the Effect on Racial Disparity

Title –  Reducing Health Disparities among Adolescents & Young Adults (AYA) by Improving their Access to Children’s Oncology Group (COG) Clinical Trials

Funder – IL Dept of Public Health (IDPH)

Title – University of Illinois Administrative Perinatal Center

Funder – Gerber Foundation

Title – Optimizing Intravenous Protein Nutrition in Premature Infants Using Urine Metabolomics

Funder – Duke Clinical Research Institute (Prime Sponsor: NIH)

Title – Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia

Funder – Children’s Oncology Group/Children’s Hospital of Philadelphia (Prime sponsor: NIH), St Baldrick’s Foundation, Circle of Service Foundation

Title – Many cancer studies

Funder – Tulane Education Fund (Admin)

Title – Pediatric HIV/AIDS Cohort Study- Tulane


UIC is one of 14 sites across the country and Puerto Rico enrolling
pregnant women who are HIV-positive in the Surveillance Monitoring for ART Toxicities study (SMARTT) study to examine the long-term safety of fetal and infant exposure to prophylactic antiretroviral (ART) chemotherapy.

Title – A Retrospective Analysis of Acute Kidney Injury in VLBW Infants

Funder – Univ of WA (Primary sponsor: NIH NINDS)

Title – Preterm Epo Neuroprotection Trial (PENUT Trial) CCC


The aim of this NINDS funded trial is to assess whether high dose Epo will improve survival without neurodevelopmental impairment (NDI) in infants born between 24 and 28 weeks of gestation (term is 40 weeks). 940 infants will be enrolled at 16 centers across the U.S. Subjects will be assessed at 2 years of age to see whether Epo treatment will improve neurodevelopmental outcomes.

Title – Evaluation of Atopy as a Pre-Existing Risk Factor for Hypersensitivity to Asparaginase in Patients with Pediatric Acute Lymphoblastic Leukemia

Title – Vaccination Status in Pediatric Cancer Survivors: Assessment of Knowledge and Barriers to Compliance

Title – North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS)

FunderPfizer Inc.

Title – An Open-Label Study to Evaluate the Safety And Pharmacokinetics Of Pf-06412528 in Children 7-17 Years for the Treatment of Moderate-to-Severe Pain B4541006 ( WIRB # 20160062 )

Title – Blood Pressure Trends in Very Low-Birth Weight Infants and Contributors of Neonatal Hypertension